CardioVision™
Development Status
Rougier Biotech - 1984 - 1998
• 1984 - the CardioVision™ Idea conceived by Prof.Phil Gold
of McGill University in Montreal
• Research, Development, Validation
• Manufacturing Plant
• IND Submission to FDA, TPP
• Phase I and II Clinical Trials completed
• Phase III - 80 Patients
Erfa Biotech - 1999 - 2005
• Acquisition of CardioVision™ and Monoclonal Antibodies from
Rougier Biotech
• Validation of the CardioVision™ Concept
• Production and availability of 9000 Vials for Clinical Research
• IND’s approved by FDA, TPP and EMEA
• Patent protection
Erfa Biotech - 2002 - 2012
• Phase III will be completed
• Submission of registration file in Canada and the United States
• Market launch in Canada and therapeutic developments
• Recovery process of cardiac muscle tissue after myocardial infarction
 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
||||
 |
 |
 |
 |
 |
|
||||
 |
|
||||||||